SlideShare a Scribd company logo
PHARMACOKINETICS
DR.MUHAMMAD USMAN KHALID
DPT,MS-NMPT
DEFINITION
• The study of “kinetics” or movement of a drug in the body
DISTRIBUTION OF DRUGS
The movement of a
drug from the blood
stream to various
tissues of the body
DISTRIBUTION OF DRUGS
•A drug reversibly leaves
the blood stream and
enters the interstitium
(ECF) and/or the cells of
the body
Distribution of drug
in the absence of elimination
Distribution of drug
in the absence of elimination
Distribution of drug
when elimination is present
Log scale of drug
distribution
THE DISTRIBUTION OF DRUG DEPENDS
ON
• Differences in regional blood flow,
determine the rate of uptake of drug
• Capillary permeability & Special
Barriers ---- BBB, placental barrier
• Drug structure - lipid solubility,
ionization
• Binding of drugs to
macromolecules
BLOOD FLOW AND DRUG DISTRIBUTION
• The initial rate of distribution of a drug depends heavily on blood flow to
various organs
• Brain, liver, kidney > muscle, skin > fat, bone
• At equilibrium, or steady state, the amount of drug in an organ is related to
mass of the organ and its properties, as well as to the properties of the
specific drug
BLOOD FLOW AND DRUG DISTRIBUTION
• Size of the organ – and concentration gradient
• Skeletal muscle –blood tissue gradient remains high even after a relatively
large amount of the drug has been transferred
• Brain – blood tissue gradient reduced to zero on distribution of a smaller
amount of drug, preventing further uptake of drug.
DRUG REDISTRIBUTION
• The relative distribution of a drug in the body changes with time
• This is seen with highly lipophilic drugs such as thiopental
• I/v thiopental produce short duration of hypnosis
• GA in 10-20seconds, effect stops 5-15 minutes due to redistribution
• – initial high concentration achieved in brain (blood flow + lipid solubility of
drug)--- then slow distribution to skeletal muscle and adipose tissue
(redistribution)
Permeability and Special Barriers to drug distribution
BBB, placental barrier
Drug structure --- lipid solubility, ionization
BBB
• BBB may not be fully developed at birth
• Inflammation, such as that result
from meningitis, may increase the
ability of ionized, poorly soluble
drugs to cross the BBB
11/9/201111/9/2011
RedistributionRedistribution
11/9/201111/9/2011
BLOODBLOOD
PLACENTAL BARRIER
• Lipid soluble drugs cross the placental barrier more easily than polar drugs;
drugs with a molecular weight of less than 600 pass the placental better
than larger molecule
• The possibility that drug administered to the mother may cross the placenta
and reach the fetus is an important consideration in therapy
• Drug transporter e.g., P-glycoprotein transporter transfer drugs out of the
fetus
CAPILLARY PERMEABILITY --LIVER &
SPLEEN
• large, discontinuous capillaries
through which large plasma
proteins can pass
• Drugs exchange freely between
blood and interstitium in the liver
BINDING OF DRUGS
TO PROTEINS
INERT BINDING
(DRUG +
NONREGULATORY
MOLECULES --- NO
EFFECT)
THE DRUGS EXISTS IN PLASMA IN THE FREE
FORM OR BOUND TO PLASMA PROTEINS
D + S DS
Free binding complex
drug site
• Extent of binding is highly variable --- 0% to 99
• The free drug is maintained as a constant fraction
of the total drug
• When the free drug levels fall, the bound drug is
releases
• Only the free drug diffuses through the capillary
walls
• Drug bound to proteins is a nondiffusible form–
it serves as a store (reservoir) & the drug is
released when the free drug levels fall
• Only free drug is available for pharmacological
action, metabolism, and excretion
• It is the free drug in the interstitial fluid that
exerts a pharmacological effect
• The amount of a drug that is bound to
protein depends upon
• The concentration of free drug
• Its affinity for binding site
• The concentration of protein
• Saturable binding sometimes leads to non-
linear relation between dose and free
(active) drug concentration
• Plasma albumin is most important; β globulin and acid glycoprotein also
bind some drugs
• Plasma albumin binds mainly acidic drugs
• 2 molecules per albumin molecule.
• Warfarin, NSAIDS, Sufonamides
• Basic drugs may be bound by β globulin & acid glycoprotein-- Quinine
CLINICAL SIGNIFICANCE OF PLASMA
PROTEIN BINDING
• Extensive protein binding
• Prolongs duration of action of the drug
• Slows drug elimination(metabolism and / or elimination)
• CRF and CLD results in hypoalbuminemia with ↓ binding of
drugs
• Drug interaction
• Many drugs may compete the same binding sites.
• Thus one drug may displace another from the binding
sites resulting in toxicity
• indomethacin displaces warfarin from protein binding
sites leading to increase warfarin levels
• Tolubutamide (95% bound) displaced by a sulphonamide
• Chloroquine strongly bounds to extravascular tissue protein
DISTRIBUTION -- WHERE THE DRUG
GOES?
• The drug is distributed to
various fluid compartments of
the body
-Volumes of distribution
-Apparent spaces
Total body fluid (42 liters)
in a 70 Kg adult
Total body fluid (42 liters)
Hydrophobic small molecule --- ethanol
Total body fluid (42 liters)
Hydrophobic small molecule --- ethanol
Hydrophilic
low molecular weight
---Aminoglycoside
---Gentamicin
Total body fluid (42 liters)
Hydrophobic small molecule --- ethanol
Hydrophilic
low molecular weight
---Aminoglycoside
---Gentamicin
Protein bound molecules
Very large molecules --- heparin
EXTRACELLULAR FLUID
Drugs that have a low molecular weight
but are hydrophilic --- Example
Atracuronium 11 L (8-15)
Plasma compartment
Very high molecular weight drugs, or
drugs that bind to plasma proteins
excessively
Example: heparin 4L (3-5)
Fat (0.2-0.35 L/Kg) ---
highly lipid soluble molecules --- DDT
Bone (0.07 L/Kg)
certain ions --- lead, fluoride
Vd equal to or higher than total body water
Diffusion to intracelullar fluid .
Vd equal to total body water.
Ethanol 38 L (34-41)
Drug that binds strongly to tissues.
Vd higher than total body water.
Fentanyl: 280 L
Propofol: 560 L
Digoxin : 385 L
APPARENT VOLUME
OF DISTRIBUTION
(VD)
IT IS THE VOLUME OF TOTAL BODY FLUID INTO WHICH A
DRUG “APPEARS” TO DISTRIBUTE
Vd = amount of drug in the body(dose)
plasma concentration
Vd is expressed as in units of volume
APPARENT VOLUME OF DISTRIBUTION
(VD)
• Most drugs distribute unevenly in several compartments
• Apparent volume of distribution assumes that the drug distributes uniformly
in a single compartment
• In most cases , the “initial” plasma concentration, C0, is determined by extrapolation
from the elimination phase
FEATURES OF VD
• The higher the Vd, the lower the
plasma concentration and vice
versa.
• A very low Vd value may indicate
extensive plasma protein binding
of the drug.
FEATURES OF VD
• A very high Vd value may indicate
that the drug is extensively bound to
the tissue sites
• An exceptional large Vd indicate
considerable sequestration of the
drug in some organ or the
compartment
A very high Vd
A very low Vd
Vd equal to or higher than total body water
Diffusion to intracelullar fluid .
Vd equal to total body water.
Ethanol 38 L (34-41)
Drug that binds strongly to tissues.
Vd higher than total body water.
Fentanyl: 280 L
Propofol: 560 L
Digoxin : 385 L
SIGNIFICANCE OF VD
• To calculate the loading dose of a drug
• Drug displacement, Vd & drug
interaction
• Vd and half life of a drug
• Vd can be used to calculate the amount
of drug needed to achieve a desired
plasma concentration
VD AND DRUG DOSAGE
• To calculate the loading dose of a drug -------Drugs with large Vd need a
loading dose to achieve the desired plasma concentration
• Vd can be used to calculate the amount of drug needed to achieve a desired
plasma concentration
• (Vd ) (C1) = amount of drug initially in the body
• (Vd ) (C2) = amount of drug needed to achieve the desired plasma drug
concentration
• Additional dose needed = Vd (C2 – C1)
DRUG DISPLACEMENT, VD &
DRUG INTERACTION
• A very low Vd value indicate extensive plasma protein binding of the drug.
• Displacement of drug from albumin --- ↑in the “free” drug
• If the therapeutic index of the drug is small. An ↑ in free drug concentration
may lead to
• ↑ therapeutic effects
• ↑ toxic effects
• Tolubutamide (95% bound) displaced by a sulphonamide
EFFECT OF A LARGE VD ON HALF LIFE OF
A DRUG
• A very large Vd indicate that most
of the drug is in the extraplasmic
space and is unavailable to
excretory organs. --- the longer is
half life and the duration of
action of the drug
• Vd may be influenced by age, sex, weight, and disease processes – edema,
ascities
• The Vd is altered by diseases
• For drugs that are normally bound to plasma protein
• Liver disease – through reduce protein synthesis
• Kidney disease – through urinary protein loss
• An exceptional large Vd
• For drugs that avidly bound in peripheral tissues, the drug’s concentration in plasma may drop
to very low values even though the total amount in the body is very large
• Vd is 50,000 liters for quinacrine
DRUG DISTRIBUTION
• Blood flow
• Capillary permeability
• Binding of drugs to plasma proteins and tissues
• Binding to plasma proteins
• Binding to tisssue proteins
• Hydrophobicity
• Volume of distribution
THANK YOU!

More Related Content

What's hot

Pharmacokinetics
PharmacokineticsPharmacokinetics
Pharmacokinetics
Rajan Kumar
 
Non linear pharmacokinetics
Non linear pharmacokineticsNon linear pharmacokinetics
Non linear pharmacokinetics
Shashi Yadav
 
Area under the curve- Dr ASHWIN R
Area under the curve- Dr ASHWIN RArea under the curve- Dr ASHWIN R
Area under the curve- Dr ASHWIN R
ashwin ravi
 
Advesre drug reaction- Types, Reporting, Evaluation, Monitoring, Preventing &...
Advesre drug reaction- Types, Reporting, Evaluation, Monitoring, Preventing &...Advesre drug reaction- Types, Reporting, Evaluation, Monitoring, Preventing &...
Advesre drug reaction- Types, Reporting, Evaluation, Monitoring, Preventing &...
Suhas Reddy C
 
Therapeutic Drug Monitoring
Therapeutic Drug MonitoringTherapeutic Drug Monitoring
Therapeutic Drug Monitoring
Dr. Ramesh Bhandari
 
Distribution of drugs
Distribution of drugsDistribution of drugs
Distribution of drugs
Viraj Shinde
 
Pharmacokinetics of drugs
Pharmacokinetics of drugsPharmacokinetics of drugs
Pharmacokinetics of drugs
kavya m
 
Pharma co kinetics compartmental modeling
Pharma co kinetics compartmental modeling Pharma co kinetics compartmental modeling
Pharma co kinetics compartmental modeling
Manjit Kaur
 
Pharmacokinetics variations in Disease States.
Pharmacokinetics variations in Disease States.Pharmacokinetics variations in Disease States.
Pharmacokinetics variations in Disease States.
Faizan Akram
 
Drug Elimination
Drug EliminationDrug Elimination
Drug Elimination
UsmanKhalid135
 
Physiologic, pharmacokinetic models, statistic moment,.pptx
Physiologic, pharmacokinetic models, statistic moment,.pptxPhysiologic, pharmacokinetic models, statistic moment,.pptx
Physiologic, pharmacokinetic models, statistic moment,.pptx
MdHimelAhmedRidoy1
 
Kinetics of ADME by Mukesh Jaiswal
Kinetics of ADME by Mukesh JaiswalKinetics of ADME by Mukesh Jaiswal
Kinetics of ADME by Mukesh Jaiswal
Mukesh Jaiswal
 
Lectures 12 Plasma Half Life and steady state concentrtiion
Lectures 12 Plasma Half Life and steady state concentrtiionLectures 12 Plasma Half Life and steady state concentrtiion
Lectures 12 Plasma Half Life and steady state concentrtiion
Isra Institute of Rehab Sciences (IIRS), Isra University
 
Therapeutic drug monitoring
Therapeutic drug monitoringTherapeutic drug monitoring
Therapeutic drug monitoringNaser Tadvi
 
Bioavailability
BioavailabilityBioavailability
Budget- Its preparation and implementation
Budget- Its preparation and implementationBudget- Its preparation and implementation
Budget- Its preparation and implementation
Subhash Yende
 
Dose adjustment in Renal failure
Dose adjustment in Renal failure Dose adjustment in Renal failure
Dose adjustment in Renal failure
Mallinath Paramgond
 
Dose adjustment in Renal Disorders
Dose adjustment in Renal DisordersDose adjustment in Renal Disorders
Dose adjustment in Renal Disorders
Dr. Ramesh Bhandari
 
Drug information center
Drug  information centerDrug  information center
Drug information center
PARUL UNIVERSITY
 
Dr.Lavanya - Factors modifying drug effect
Dr.Lavanya - Factors modifying drug effectDr.Lavanya - Factors modifying drug effect
Dr.Lavanya - Factors modifying drug effect
Dr.Lavanya .S.A
 

What's hot (20)

Pharmacokinetics
PharmacokineticsPharmacokinetics
Pharmacokinetics
 
Non linear pharmacokinetics
Non linear pharmacokineticsNon linear pharmacokinetics
Non linear pharmacokinetics
 
Area under the curve- Dr ASHWIN R
Area under the curve- Dr ASHWIN RArea under the curve- Dr ASHWIN R
Area under the curve- Dr ASHWIN R
 
Advesre drug reaction- Types, Reporting, Evaluation, Monitoring, Preventing &...
Advesre drug reaction- Types, Reporting, Evaluation, Monitoring, Preventing &...Advesre drug reaction- Types, Reporting, Evaluation, Monitoring, Preventing &...
Advesre drug reaction- Types, Reporting, Evaluation, Monitoring, Preventing &...
 
Therapeutic Drug Monitoring
Therapeutic Drug MonitoringTherapeutic Drug Monitoring
Therapeutic Drug Monitoring
 
Distribution of drugs
Distribution of drugsDistribution of drugs
Distribution of drugs
 
Pharmacokinetics of drugs
Pharmacokinetics of drugsPharmacokinetics of drugs
Pharmacokinetics of drugs
 
Pharma co kinetics compartmental modeling
Pharma co kinetics compartmental modeling Pharma co kinetics compartmental modeling
Pharma co kinetics compartmental modeling
 
Pharmacokinetics variations in Disease States.
Pharmacokinetics variations in Disease States.Pharmacokinetics variations in Disease States.
Pharmacokinetics variations in Disease States.
 
Drug Elimination
Drug EliminationDrug Elimination
Drug Elimination
 
Physiologic, pharmacokinetic models, statistic moment,.pptx
Physiologic, pharmacokinetic models, statistic moment,.pptxPhysiologic, pharmacokinetic models, statistic moment,.pptx
Physiologic, pharmacokinetic models, statistic moment,.pptx
 
Kinetics of ADME by Mukesh Jaiswal
Kinetics of ADME by Mukesh JaiswalKinetics of ADME by Mukesh Jaiswal
Kinetics of ADME by Mukesh Jaiswal
 
Lectures 12 Plasma Half Life and steady state concentrtiion
Lectures 12 Plasma Half Life and steady state concentrtiionLectures 12 Plasma Half Life and steady state concentrtiion
Lectures 12 Plasma Half Life and steady state concentrtiion
 
Therapeutic drug monitoring
Therapeutic drug monitoringTherapeutic drug monitoring
Therapeutic drug monitoring
 
Bioavailability
BioavailabilityBioavailability
Bioavailability
 
Budget- Its preparation and implementation
Budget- Its preparation and implementationBudget- Its preparation and implementation
Budget- Its preparation and implementation
 
Dose adjustment in Renal failure
Dose adjustment in Renal failure Dose adjustment in Renal failure
Dose adjustment in Renal failure
 
Dose adjustment in Renal Disorders
Dose adjustment in Renal DisordersDose adjustment in Renal Disorders
Dose adjustment in Renal Disorders
 
Drug information center
Drug  information centerDrug  information center
Drug information center
 
Dr.Lavanya - Factors modifying drug effect
Dr.Lavanya - Factors modifying drug effectDr.Lavanya - Factors modifying drug effect
Dr.Lavanya - Factors modifying drug effect
 

Similar to Pharmacokinetics Drug Distribution

4_DISTRIBUTION.pptx
4_DISTRIBUTION.pptx4_DISTRIBUTION.pptx
4_DISTRIBUTION.pptx
JoshuaKalunda
 
Distribution of drug
Distribution of drugDistribution of drug
Distribution of drug
Dr.I.SHEIK NASAR
 
Distribution of drugs Pharmacokinetics
Distribution of drugs PharmacokineticsDistribution of drugs Pharmacokinetics
Distribution of drugs Pharmacokinetics
Jaineel Dharod
 
biopharm3.pptx
biopharm3.pptxbiopharm3.pptx
biopharm3.pptx
AliElmehdawi2
 
05.1 drug distribution
05.1 drug distribution05.1 drug distribution
05.1 drug distribution
RichardPaul54
 
05.0 drug distribution
05.0 drug distribution05.0 drug distribution
05.0 drug distribution
RichardPaul54
 
Distribution of drugs
Distribution of drugsDistribution of drugs
Distribution of drugs
Dipak Bari
 
Clinical pharmacokinetics & pharmacodynamics 1
Clinical pharmacokinetics & pharmacodynamics 1Clinical pharmacokinetics & pharmacodynamics 1
Clinical pharmacokinetics & pharmacodynamics 1
BhushanSurana2
 
Drug distribution
Drug distributionDrug distribution
Drug distribution
Naser Tadvi
 
Pharmacokinetics class 2
Pharmacokinetics   class 2Pharmacokinetics   class 2
Pharmacokinetics class 2
candyshridhar24
 
Drug distribution and its clinical significance
Drug distribution and its clinical significanceDrug distribution and its clinical significance
Drug distribution and its clinical significance
DeepakPandey379
 
Toxicokinetics studies by vikas gupta.pptx
Toxicokinetics studies by vikas gupta.pptxToxicokinetics studies by vikas gupta.pptx
Toxicokinetics studies by vikas gupta.pptx
VikasGupta530537
 
Drug Distribution.pdf
Drug Distribution.pdfDrug Distribution.pdf
Drug Distribution.pdf
Shaikh Abusufyan
 
drug drugdistribut 1
drug drugdistribut 1drug drugdistribut 1
drug drugdistribut 1AMAL MOHAMMED
 
Distribution of Drugs and physiological barriers .pptx
Distribution of Drugs and physiological barriers .pptxDistribution of Drugs and physiological barriers .pptx
Distribution of Drugs and physiological barriers .pptx
silpaceutics
 
Pharmacokinetics absorption and distribution
Pharmacokinetics absorption and distributionPharmacokinetics absorption and distribution
Pharmacokinetics absorption and distribution
sumitmahato20
 
Drug Distribution.pptx
Drug Distribution.pptxDrug Distribution.pptx
Drug Distribution.pptx
Awais irshad
 
Drug distribution
Drug distributionDrug distribution
Drug distribution
uroojumer1
 

Similar to Pharmacokinetics Drug Distribution (20)

4_DISTRIBUTION.pptx
4_DISTRIBUTION.pptx4_DISTRIBUTION.pptx
4_DISTRIBUTION.pptx
 
Distribution of drug
Distribution of drugDistribution of drug
Distribution of drug
 
Distribution of drugs Pharmacokinetics
Distribution of drugs PharmacokineticsDistribution of drugs Pharmacokinetics
Distribution of drugs Pharmacokinetics
 
biopharm3.pptx
biopharm3.pptxbiopharm3.pptx
biopharm3.pptx
 
05.1 drug distribution
05.1 drug distribution05.1 drug distribution
05.1 drug distribution
 
05.0 drug distribution
05.0 drug distribution05.0 drug distribution
05.0 drug distribution
 
Distribution of drugs
Distribution of drugsDistribution of drugs
Distribution of drugs
 
Clinical pharmacokinetics & pharmacodynamics 1
Clinical pharmacokinetics & pharmacodynamics 1Clinical pharmacokinetics & pharmacodynamics 1
Clinical pharmacokinetics & pharmacodynamics 1
 
Drug distribution
Drug distributionDrug distribution
Drug distribution
 
Pharmacokinetics class 2
Pharmacokinetics   class 2Pharmacokinetics   class 2
Pharmacokinetics class 2
 
Drug distribution and its clinical significance
Drug distribution and its clinical significanceDrug distribution and its clinical significance
Drug distribution and its clinical significance
 
Toxicokinetics studies by vikas gupta.pptx
Toxicokinetics studies by vikas gupta.pptxToxicokinetics studies by vikas gupta.pptx
Toxicokinetics studies by vikas gupta.pptx
 
Drug Distribution.pdf
Drug Distribution.pdfDrug Distribution.pdf
Drug Distribution.pdf
 
Pharmacokinetics
PharmacokineticsPharmacokinetics
Pharmacokinetics
 
drug drugdistribut 1
drug drugdistribut 1drug drugdistribut 1
drug drugdistribut 1
 
Distribution of Drugs and physiological barriers .pptx
Distribution of Drugs and physiological barriers .pptxDistribution of Drugs and physiological barriers .pptx
Distribution of Drugs and physiological barriers .pptx
 
Pharmacokinetics absorption and distribution
Pharmacokinetics absorption and distributionPharmacokinetics absorption and distribution
Pharmacokinetics absorption and distribution
 
Drug distribution & clearance
Drug distribution & clearanceDrug distribution & clearance
Drug distribution & clearance
 
Drug Distribution.pptx
Drug Distribution.pptxDrug Distribution.pptx
Drug Distribution.pptx
 
Drug distribution
Drug distributionDrug distribution
Drug distribution
 

More from UsmanKhalid135

Sympathomimetics
SympathomimeticsSympathomimetics
Sympathomimetics
UsmanKhalid135
 
Introduction to autonomic pharmacology
Introduction to autonomic pharmacologyIntroduction to autonomic pharmacology
Introduction to autonomic pharmacology
UsmanKhalid135
 
Cholinoceptor activating and cholinesterase-inhibiting drugs
Cholinoceptor activating and cholinesterase-inhibiting drugsCholinoceptor activating and cholinesterase-inhibiting drugs
Cholinoceptor activating and cholinesterase-inhibiting drugs
UsmanKhalid135
 
Cholinoceptor Blockers
Cholinoceptor BlockersCholinoceptor Blockers
Cholinoceptor Blockers
UsmanKhalid135
 
Adrenergic Receptor Blockers
Adrenergic Receptor BlockersAdrenergic Receptor Blockers
Adrenergic Receptor Blockers
UsmanKhalid135
 
Pharmacokinetics Drug Transportation
Pharmacokinetics  Drug TransportationPharmacokinetics  Drug Transportation
Pharmacokinetics Drug Transportation
UsmanKhalid135
 
Pharmacodynamics
PharmacodynamicsPharmacodynamics
Pharmacodynamics
UsmanKhalid135
 
Introduction to Pharmacology
Introduction to PharmacologyIntroduction to Pharmacology
Introduction to Pharmacology
UsmanKhalid135
 
Bioavailability
BioavailabilityBioavailability
Bioavailability
UsmanKhalid135
 
Opioid Analgesics
Opioid AnalgesicsOpioid Analgesics
Opioid Analgesics
UsmanKhalid135
 
Drugs in Parkinsonism
Drugs in ParkinsonismDrugs in Parkinsonism
Drugs in Parkinsonism
UsmanKhalid135
 
Anti Pscychotic Drugs
Anti Pscychotic DrugsAnti Pscychotic Drugs
Anti Pscychotic Drugs
UsmanKhalid135
 
Anti Depressive Drugs
Anti Depressive DrugsAnti Depressive Drugs
Anti Depressive Drugs
UsmanKhalid135
 
Drugs Used in Hypertension
Drugs Used in HypertensionDrugs Used in Hypertension
Drugs Used in Hypertension
UsmanKhalid135
 
Drugs used in Heart Failure
Drugs used in Heart FailureDrugs used in Heart Failure
Drugs used in Heart Failure
UsmanKhalid135
 
Drugs Used In Angina
Drugs Used In AnginaDrugs Used In Angina
Drugs Used In Angina
UsmanKhalid135
 
Antiarrhythmic drugs
Antiarrhythmic drugsAntiarrhythmic drugs
Antiarrhythmic drugs
UsmanKhalid135
 
Nsaids, Acetaminophen
Nsaids, AcetaminophenNsaids, Acetaminophen
Nsaids, Acetaminophen
UsmanKhalid135
 
Coagulation Disorders
Coagulation DisordersCoagulation Disorders
Coagulation Disorders
UsmanKhalid135
 
Skeletal Muscle Relaxants
Skeletal Muscle RelaxantsSkeletal Muscle Relaxants
Skeletal Muscle Relaxants
UsmanKhalid135
 

More from UsmanKhalid135 (20)

Sympathomimetics
SympathomimeticsSympathomimetics
Sympathomimetics
 
Introduction to autonomic pharmacology
Introduction to autonomic pharmacologyIntroduction to autonomic pharmacology
Introduction to autonomic pharmacology
 
Cholinoceptor activating and cholinesterase-inhibiting drugs
Cholinoceptor activating and cholinesterase-inhibiting drugsCholinoceptor activating and cholinesterase-inhibiting drugs
Cholinoceptor activating and cholinesterase-inhibiting drugs
 
Cholinoceptor Blockers
Cholinoceptor BlockersCholinoceptor Blockers
Cholinoceptor Blockers
 
Adrenergic Receptor Blockers
Adrenergic Receptor BlockersAdrenergic Receptor Blockers
Adrenergic Receptor Blockers
 
Pharmacokinetics Drug Transportation
Pharmacokinetics  Drug TransportationPharmacokinetics  Drug Transportation
Pharmacokinetics Drug Transportation
 
Pharmacodynamics
PharmacodynamicsPharmacodynamics
Pharmacodynamics
 
Introduction to Pharmacology
Introduction to PharmacologyIntroduction to Pharmacology
Introduction to Pharmacology
 
Bioavailability
BioavailabilityBioavailability
Bioavailability
 
Opioid Analgesics
Opioid AnalgesicsOpioid Analgesics
Opioid Analgesics
 
Drugs in Parkinsonism
Drugs in ParkinsonismDrugs in Parkinsonism
Drugs in Parkinsonism
 
Anti Pscychotic Drugs
Anti Pscychotic DrugsAnti Pscychotic Drugs
Anti Pscychotic Drugs
 
Anti Depressive Drugs
Anti Depressive DrugsAnti Depressive Drugs
Anti Depressive Drugs
 
Drugs Used in Hypertension
Drugs Used in HypertensionDrugs Used in Hypertension
Drugs Used in Hypertension
 
Drugs used in Heart Failure
Drugs used in Heart FailureDrugs used in Heart Failure
Drugs used in Heart Failure
 
Drugs Used In Angina
Drugs Used In AnginaDrugs Used In Angina
Drugs Used In Angina
 
Antiarrhythmic drugs
Antiarrhythmic drugsAntiarrhythmic drugs
Antiarrhythmic drugs
 
Nsaids, Acetaminophen
Nsaids, AcetaminophenNsaids, Acetaminophen
Nsaids, Acetaminophen
 
Coagulation Disorders
Coagulation DisordersCoagulation Disorders
Coagulation Disorders
 
Skeletal Muscle Relaxants
Skeletal Muscle RelaxantsSkeletal Muscle Relaxants
Skeletal Muscle Relaxants
 

Recently uploaded

aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
siemaillard
 
Model Attribute Check Company Auto Property
Model Attribute  Check Company Auto PropertyModel Attribute  Check Company Auto Property
Model Attribute Check Company Auto Property
Celine George
 
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
EugeneSaldivar
 
special B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdfspecial B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdf
Special education needs
 
Introduction to AI for Nonprofits with Tapp Network
Introduction to AI for Nonprofits with Tapp NetworkIntroduction to AI for Nonprofits with Tapp Network
Introduction to AI for Nonprofits with Tapp Network
TechSoup
 
Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.
Ashokrao Mane college of Pharmacy Peth-Vadgaon
 
The basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptxThe basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptx
heathfieldcps1
 
Marketing internship report file for MBA
Marketing internship report file for MBAMarketing internship report file for MBA
Marketing internship report file for MBA
gb193092
 
Supporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptxSupporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptx
Jisc
 
The French Revolution Class 9 Study Material pdf free download
The French Revolution Class 9 Study Material pdf free downloadThe French Revolution Class 9 Study Material pdf free download
The French Revolution Class 9 Study Material pdf free download
Vivekanand Anglo Vedic Academy
 
Overview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with MechanismOverview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with Mechanism
DeeptiGupta154
 
A Survey of Techniques for Maximizing LLM Performance.pptx
A Survey of Techniques for Maximizing LLM Performance.pptxA Survey of Techniques for Maximizing LLM Performance.pptx
A Survey of Techniques for Maximizing LLM Performance.pptx
thanhdowork
 
A Strategic Approach: GenAI in Education
A Strategic Approach: GenAI in EducationA Strategic Approach: GenAI in Education
A Strategic Approach: GenAI in Education
Peter Windle
 
Embracing GenAI - A Strategic Imperative
Embracing GenAI - A Strategic ImperativeEmbracing GenAI - A Strategic Imperative
Embracing GenAI - A Strategic Imperative
Peter Windle
 
Francesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptxFrancesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptx
EduSkills OECD
 
Operation Blue Star - Saka Neela Tara
Operation Blue Star   -  Saka Neela TaraOperation Blue Star   -  Saka Neela Tara
Operation Blue Star - Saka Neela Tara
Balvir Singh
 
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
Levi Shapiro
 
Best Digital Marketing Institute In NOIDA
Best Digital Marketing Institute In NOIDABest Digital Marketing Institute In NOIDA
Best Digital Marketing Institute In NOIDA
deeptiverma2406
 
Guidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th SemesterGuidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th Semester
Atul Kumar Singh
 
CACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdfCACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdf
camakaiclarkmusic
 

Recently uploaded (20)

aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
 
Model Attribute Check Company Auto Property
Model Attribute  Check Company Auto PropertyModel Attribute  Check Company Auto Property
Model Attribute Check Company Auto Property
 
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
 
special B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdfspecial B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdf
 
Introduction to AI for Nonprofits with Tapp Network
Introduction to AI for Nonprofits with Tapp NetworkIntroduction to AI for Nonprofits with Tapp Network
Introduction to AI for Nonprofits with Tapp Network
 
Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.
 
The basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptxThe basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptx
 
Marketing internship report file for MBA
Marketing internship report file for MBAMarketing internship report file for MBA
Marketing internship report file for MBA
 
Supporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptxSupporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptx
 
The French Revolution Class 9 Study Material pdf free download
The French Revolution Class 9 Study Material pdf free downloadThe French Revolution Class 9 Study Material pdf free download
The French Revolution Class 9 Study Material pdf free download
 
Overview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with MechanismOverview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with Mechanism
 
A Survey of Techniques for Maximizing LLM Performance.pptx
A Survey of Techniques for Maximizing LLM Performance.pptxA Survey of Techniques for Maximizing LLM Performance.pptx
A Survey of Techniques for Maximizing LLM Performance.pptx
 
A Strategic Approach: GenAI in Education
A Strategic Approach: GenAI in EducationA Strategic Approach: GenAI in Education
A Strategic Approach: GenAI in Education
 
Embracing GenAI - A Strategic Imperative
Embracing GenAI - A Strategic ImperativeEmbracing GenAI - A Strategic Imperative
Embracing GenAI - A Strategic Imperative
 
Francesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptxFrancesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptx
 
Operation Blue Star - Saka Neela Tara
Operation Blue Star   -  Saka Neela TaraOperation Blue Star   -  Saka Neela Tara
Operation Blue Star - Saka Neela Tara
 
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
 
Best Digital Marketing Institute In NOIDA
Best Digital Marketing Institute In NOIDABest Digital Marketing Institute In NOIDA
Best Digital Marketing Institute In NOIDA
 
Guidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th SemesterGuidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th Semester
 
CACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdfCACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdf
 

Pharmacokinetics Drug Distribution

  • 2. DEFINITION • The study of “kinetics” or movement of a drug in the body
  • 3.
  • 4.
  • 5.
  • 6.
  • 7. DISTRIBUTION OF DRUGS The movement of a drug from the blood stream to various tissues of the body
  • 8. DISTRIBUTION OF DRUGS •A drug reversibly leaves the blood stream and enters the interstitium (ECF) and/or the cells of the body
  • 9.
  • 10.
  • 11.
  • 12.
  • 13. Distribution of drug in the absence of elimination
  • 14.
  • 15. Distribution of drug in the absence of elimination
  • 16. Distribution of drug when elimination is present
  • 17.
  • 18.
  • 19. Log scale of drug distribution
  • 20.
  • 21. THE DISTRIBUTION OF DRUG DEPENDS ON • Differences in regional blood flow, determine the rate of uptake of drug • Capillary permeability & Special Barriers ---- BBB, placental barrier • Drug structure - lipid solubility, ionization • Binding of drugs to macromolecules
  • 22. BLOOD FLOW AND DRUG DISTRIBUTION • The initial rate of distribution of a drug depends heavily on blood flow to various organs • Brain, liver, kidney > muscle, skin > fat, bone • At equilibrium, or steady state, the amount of drug in an organ is related to mass of the organ and its properties, as well as to the properties of the specific drug
  • 23. BLOOD FLOW AND DRUG DISTRIBUTION • Size of the organ – and concentration gradient • Skeletal muscle –blood tissue gradient remains high even after a relatively large amount of the drug has been transferred • Brain – blood tissue gradient reduced to zero on distribution of a smaller amount of drug, preventing further uptake of drug.
  • 24. DRUG REDISTRIBUTION • The relative distribution of a drug in the body changes with time • This is seen with highly lipophilic drugs such as thiopental • I/v thiopental produce short duration of hypnosis • GA in 10-20seconds, effect stops 5-15 minutes due to redistribution • – initial high concentration achieved in brain (blood flow + lipid solubility of drug)--- then slow distribution to skeletal muscle and adipose tissue (redistribution)
  • 25. Permeability and Special Barriers to drug distribution BBB, placental barrier Drug structure --- lipid solubility, ionization
  • 26.
  • 27. BBB • BBB may not be fully developed at birth • Inflammation, such as that result from meningitis, may increase the ability of ionized, poorly soluble drugs to cross the BBB
  • 28.
  • 30. PLACENTAL BARRIER • Lipid soluble drugs cross the placental barrier more easily than polar drugs; drugs with a molecular weight of less than 600 pass the placental better than larger molecule • The possibility that drug administered to the mother may cross the placenta and reach the fetus is an important consideration in therapy • Drug transporter e.g., P-glycoprotein transporter transfer drugs out of the fetus
  • 31. CAPILLARY PERMEABILITY --LIVER & SPLEEN • large, discontinuous capillaries through which large plasma proteins can pass • Drugs exchange freely between blood and interstitium in the liver
  • 32.
  • 33. BINDING OF DRUGS TO PROTEINS INERT BINDING (DRUG + NONREGULATORY MOLECULES --- NO EFFECT)
  • 34. THE DRUGS EXISTS IN PLASMA IN THE FREE FORM OR BOUND TO PLASMA PROTEINS D + S DS Free binding complex drug site • Extent of binding is highly variable --- 0% to 99 • The free drug is maintained as a constant fraction of the total drug • When the free drug levels fall, the bound drug is releases
  • 35. • Only the free drug diffuses through the capillary walls • Drug bound to proteins is a nondiffusible form– it serves as a store (reservoir) & the drug is released when the free drug levels fall • Only free drug is available for pharmacological action, metabolism, and excretion • It is the free drug in the interstitial fluid that exerts a pharmacological effect
  • 36. • The amount of a drug that is bound to protein depends upon • The concentration of free drug • Its affinity for binding site • The concentration of protein • Saturable binding sometimes leads to non- linear relation between dose and free (active) drug concentration
  • 37. • Plasma albumin is most important; β globulin and acid glycoprotein also bind some drugs • Plasma albumin binds mainly acidic drugs • 2 molecules per albumin molecule. • Warfarin, NSAIDS, Sufonamides • Basic drugs may be bound by β globulin & acid glycoprotein-- Quinine
  • 38. CLINICAL SIGNIFICANCE OF PLASMA PROTEIN BINDING • Extensive protein binding • Prolongs duration of action of the drug • Slows drug elimination(metabolism and / or elimination) • CRF and CLD results in hypoalbuminemia with ↓ binding of drugs • Drug interaction • Many drugs may compete the same binding sites. • Thus one drug may displace another from the binding sites resulting in toxicity • indomethacin displaces warfarin from protein binding sites leading to increase warfarin levels • Tolubutamide (95% bound) displaced by a sulphonamide • Chloroquine strongly bounds to extravascular tissue protein
  • 39. DISTRIBUTION -- WHERE THE DRUG GOES? • The drug is distributed to various fluid compartments of the body -Volumes of distribution -Apparent spaces
  • 40. Total body fluid (42 liters) in a 70 Kg adult
  • 41. Total body fluid (42 liters) Hydrophobic small molecule --- ethanol
  • 42. Total body fluid (42 liters) Hydrophobic small molecule --- ethanol Hydrophilic low molecular weight ---Aminoglycoside ---Gentamicin
  • 43. Total body fluid (42 liters) Hydrophobic small molecule --- ethanol Hydrophilic low molecular weight ---Aminoglycoside ---Gentamicin Protein bound molecules Very large molecules --- heparin
  • 44. EXTRACELLULAR FLUID Drugs that have a low molecular weight but are hydrophilic --- Example Atracuronium 11 L (8-15)
  • 45. Plasma compartment Very high molecular weight drugs, or drugs that bind to plasma proteins excessively Example: heparin 4L (3-5)
  • 46. Fat (0.2-0.35 L/Kg) --- highly lipid soluble molecules --- DDT Bone (0.07 L/Kg) certain ions --- lead, fluoride
  • 47. Vd equal to or higher than total body water Diffusion to intracelullar fluid . Vd equal to total body water. Ethanol 38 L (34-41) Drug that binds strongly to tissues. Vd higher than total body water. Fentanyl: 280 L Propofol: 560 L Digoxin : 385 L
  • 48. APPARENT VOLUME OF DISTRIBUTION (VD) IT IS THE VOLUME OF TOTAL BODY FLUID INTO WHICH A DRUG “APPEARS” TO DISTRIBUTE
  • 49. Vd = amount of drug in the body(dose) plasma concentration Vd is expressed as in units of volume
  • 50. APPARENT VOLUME OF DISTRIBUTION (VD) • Most drugs distribute unevenly in several compartments • Apparent volume of distribution assumes that the drug distributes uniformly in a single compartment • In most cases , the “initial” plasma concentration, C0, is determined by extrapolation from the elimination phase
  • 51. FEATURES OF VD • The higher the Vd, the lower the plasma concentration and vice versa. • A very low Vd value may indicate extensive plasma protein binding of the drug.
  • 52. FEATURES OF VD • A very high Vd value may indicate that the drug is extensively bound to the tissue sites • An exceptional large Vd indicate considerable sequestration of the drug in some organ or the compartment
  • 53. A very high Vd A very low Vd
  • 54. Vd equal to or higher than total body water Diffusion to intracelullar fluid . Vd equal to total body water. Ethanol 38 L (34-41) Drug that binds strongly to tissues. Vd higher than total body water. Fentanyl: 280 L Propofol: 560 L Digoxin : 385 L
  • 55. SIGNIFICANCE OF VD • To calculate the loading dose of a drug • Drug displacement, Vd & drug interaction • Vd and half life of a drug • Vd can be used to calculate the amount of drug needed to achieve a desired plasma concentration
  • 56. VD AND DRUG DOSAGE • To calculate the loading dose of a drug -------Drugs with large Vd need a loading dose to achieve the desired plasma concentration • Vd can be used to calculate the amount of drug needed to achieve a desired plasma concentration • (Vd ) (C1) = amount of drug initially in the body • (Vd ) (C2) = amount of drug needed to achieve the desired plasma drug concentration • Additional dose needed = Vd (C2 – C1)
  • 57. DRUG DISPLACEMENT, VD & DRUG INTERACTION • A very low Vd value indicate extensive plasma protein binding of the drug. • Displacement of drug from albumin --- ↑in the “free” drug • If the therapeutic index of the drug is small. An ↑ in free drug concentration may lead to • ↑ therapeutic effects • ↑ toxic effects • Tolubutamide (95% bound) displaced by a sulphonamide
  • 58. EFFECT OF A LARGE VD ON HALF LIFE OF A DRUG • A very large Vd indicate that most of the drug is in the extraplasmic space and is unavailable to excretory organs. --- the longer is half life and the duration of action of the drug
  • 59. • Vd may be influenced by age, sex, weight, and disease processes – edema, ascities • The Vd is altered by diseases • For drugs that are normally bound to plasma protein • Liver disease – through reduce protein synthesis • Kidney disease – through urinary protein loss • An exceptional large Vd • For drugs that avidly bound in peripheral tissues, the drug’s concentration in plasma may drop to very low values even though the total amount in the body is very large • Vd is 50,000 liters for quinacrine
  • 60. DRUG DISTRIBUTION • Blood flow • Capillary permeability • Binding of drugs to plasma proteins and tissues • Binding to plasma proteins • Binding to tisssue proteins • Hydrophobicity • Volume of distribution

Editor's Notes

  1. Lippin review 9, DPT
  2. R & D 103
  3. Lipp review 9
  4. Lipp review 9
  5. Lippin 13
  6. Lippin 5th